索托拉西布治疗携带KRAS G12C突变和侵袭性播散性肺转移的转移性非典型肺类癌有效治疗的首例病例报告：病例报告

The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report.

作者信息

Saiki Masafumi, Omori Chisa, Morikawa Honami, Shinohara Ken, Shimamura So, Ohkoshi Hiroki, Uchida Yoshinori, Inoue Tomohiro, Kondo Tetsuo, Ikemura Shinnosuke, Soejima Kenzo

机构信息

Department of Respiratory Medicine, Graduate School of Medicine University of Yamanashi, Chuo, Japan.

Department of Pathology, Graduate School of Medicine University of Yamanashi, Chuo, Japan.

出版信息

JTO Clin Res Rep. 2023 Dec 15;5(1):100620. doi: 10.1016/j.jtocrr.2023.100620. eCollection 2024 Jan.

DOI:10.1016/j.jtocrr.2023.100620

PMID:38299192

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10828806/

Abstract

Pulmonary neuroendocrine tumors are rare, accounting for approximately 1% to 2% of lung cancers. Atypical carcinoids account for approximately 10% of pulmonary neuroendocrine tumors and are categorized as moderately malignant. Treatment options for advanced-stage atypical carcinoids include everolimus, cytotoxic anticancer agents, and peptide receptor radionuclide therapy. In this report, we present the first case of KRAS G12C mutation-positive atypical carcinoid that was successfully treated with sotorasib. Therapeutically important mutations observed in non-small cell lung cancer are seldom found in atypical carcinoid tumors. Nonetheless, it is worthwhile to search for genetic mutations in atypical carcinoid tumors, considering the potential for molecular targeted therapy to be effective in their treatment as well.

摘要

肺神经内分泌肿瘤较为罕见，约占肺癌的1%至2%。非典型类癌约占肺神经内分泌肿瘤的10%，被归类为中度恶性。晚期非典型类癌的治疗选择包括依维莫司、细胞毒性抗癌药物和肽受体放射性核素治疗。在本报告中，我们介绍了首例经索托拉西成功治疗的KRAS G12C突变阳性非典型类癌。在非小细胞肺癌中观察到的具有治疗意义的突变在非典型类癌肿瘤中很少见。尽管如此，考虑到分子靶向治疗在其治疗中也可能有效的可能性，在非典型类癌肿瘤中寻找基因突变是值得的。